Trial Profile
Clinical Evaluation of 18F-AV-1451
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
- Focus Adverse reactions; Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 21 Aug 2020 Status changed from active, no longer recruiting to completed.
- 15 Jan 2020 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 19 Nov 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.